CSKPL is India’s first exclusively autologous stemcell bank established in May 2003. With the first sample banked on August 25th 2003.

Therapeutic potential of stemcell has been acknowledged as one of the path breaking discoveries of the last century. Several novel therapies for treating several hitherto incurable diseases are based on the use of stemcells.

Though this advanced therapy has been prevalent in the western world, already for several years, nothing similar has been available in our country because of lack of banking service facility to Cryopreserve Stemcells (in liquid nitrogen).

With the genesis of the company this specific lacuna is taken care of effectively.

• Offering World class banking facility service for storing of umbilical cord blood stemcells, thereby ensuring you and your newborn’s future need.
  
• Short-term cryopreservation of mobilized peripheral blood stemcell for use in treatment of cancers, arranging for appropriate stemcell therapies as and when needed.
• Establishing research collaborations with academic institutions in India & abroad for promoting basic research in stemcell and with other cord blood banks.
• Supporting of NGO’s such as the Thalassemia Society.
• To create awareness by arranging lectures and seminars.
• Establishing a WORLD CLASS SPECIALITY HOSPITAL for stem cells based transplants therapy and related clinical research.
  
  

The objectives of the company are not solely commercial even though the directors are committed to creating a financially strong entity. Since the company is a knowledge based company, the directors are aware of their responsibility towards creation of new knowledge. Therefore, research will be accorded a high priority and a substantial share of the profits generated will be ploughed back into research. The company also recognizes the fact that academic institutions are perfect cradles for discovery and genesis of new knowledge. It will be company policy to promote collaborative research between cryostem and research institutes. One of the research products that would be our priority is “Development of Embryonic Stem cell Lines for Clinical Applications”.

Research will be initiated for deriving stem cell lines, which are suitable for human transplantation. Research in other areas of regenerative medicine will also be initiated. These will be finally carried out at our own specialty hospital.

The potential to cure otherwise “incurable” diseases such as Parkinson’s or Leukemia is greater than before and most of the new possibilities are not based on conventional therapies. Childhood Leukemia’s, Alzheimer’s, neural degenerative diseases such as Parkinson’s as well as Thalassemia and Diabetes, Spinal cord injury are not effectively treatable with existing therapies.

Science has always progressed because there is a necessity. The fact remains that there is a quest in us to search for newer, better and more adequate therapies, which have minimal, side effects in the human body.